Literature DB >> 3235481

Comparison of methods of carbamazepine dosage, individualization in epileptic patients.

M J Garcia1, A C Alonso, A Maza, D Santos, C Matesanz, A Dominguez-Gil.   

Abstract

The aim of the present work was to analyse the predictive capacity of different optimization methods for carbamazepine dosage regimens according to population pharmacokinetic parameters and/or serum levels data. Calculations were performed using a multiple non-linear regression program (MULTI 2 BAYES) with two different options: (a) using the ordinary least squares methods and (b) the least squares method based on the Bayesian algorithm. The predictive capacity of the three methods was analysed comparing the serum levels values in patients predicted by each method and those observed later. The performance obtained was poor and even unacceptable when dosage prediction was based on the mean parameters of the population studied (Method A) and when only one data point relating to the serum carbamazepine levels was available (Method B). When two serum levels data were used the standard deviation of the mean prediction error was only clinically acceptable when Bayesian non-linear regression was applied (Method C). When the number of serum levels data points was 3 or 4 the errors were acceptable from a clinical point of view and no significant differences could be found between the use of the simple and Bayesian version at the same level of information.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3235481     DOI: 10.1111/j.1365-2710.1988.tb00207.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  4 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  A limited sampling method for the estimation of AUC and Cmax of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product.

Authors:  I Mahmood; N Chamberlin
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

Review 3.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 4.  Pharmacokinetic optimisation of anticonvulsant therapy.

Authors:  A H Thomson; M J Brodie
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.